Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05211895
Title	A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)
Acronym	PACIFIC-8
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Durvalumab AB154 + Durvalumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| ROU \| POL \| NOR \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL